The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

The most clinically relevant new aspects of the 2019 version of the ESC Guidelines compared with the previous version published in 2013 relate to: ... The prevalence of diabetes continues to increase, with 60 million thought to have diabetes in Europe in 2017 and predictions of more than 600 million individuals with diabetes worldwide by 2045. These numbers carry a huge burden of morbidity and mortality with a high prevalence of microvascular disease affecting the eyes, nerves, and kidneys and macrovascular disease leading to CV, cerebrovascular, and peripheral vascular disease. The combination of diabetes, CKD, hypertension, and dyslipidaemia make a potent contribution to the development of CV disease and the 2019 guidelines pay particular attention to the new information from clinical trials that address the management of these issues. Whilst updating our recommendations has been a key element in the new guidelines we have continued to emphasize the importance of making individualized care decisions in collaboration with other healthcare workers and informed patients as outlined in the 2013 guidelines.